Inclisiran

Inclisiran has been studied in 109 papers since 2018: 14 trials and 34 observational studies in people, 2 in animals, 52 reviews; 95 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “PCSK9 Inhibition in Transition: From Established Treatments to Emerging Therapeutic Approaches”.

InterventionApproved 2021

109 papers study it99 findingsUpdated

39 new papers in 30 daysSee all 109 papers on inclisiran

At a glance

Independent labs found the same change in people. 40 independent labs in 21 countries; 51 trials, 7 about aging, 2 with no results posted.

“Inclisiran significantly reduced: LDL-C (WMD –48.99%, 95% CI: –54.29 to –43.69)”
Updated Meta-Analysis of Randomized Controlled Trials Evaluating the Safety and Efficacy of Inclisiran in HyperlipidemiaAHA Scientific Sessions 2025 abstract2025doi:10.1161/circ.152.suppl_3.4366962

3 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 40 independent labs in 21 countries
  • 3 findings against
  • 51 trials, 7 about aging, 2 with no results posted
  • Funders: Novartis Pharma and others
  • 33 of 86 findings with company ties
  • 39 of 51 trials sponsored by its developers
  • Human trial14
  • Humans34
  • Animals2
  • In silico3

11 studies gave inclisiran to people and measured what changed.

What changedDesignPeopleSource

down: Decreases LDL cholesterol50% reduction

down: Decreases plasma PCSK9 concentration56% reduction

Treated cohort3 months19 peopleHypercholesterolemiaAHA Scientific Sessions 2026 abstract, Nov 2, 2026

down: Decreases LDL-C51% reduction (4.8 to 2.3 mmol/L)

down: Decreases lipoprotein27% reduction (70 to 51 mg/dL)

up: Increases liver enzyme elevation6% of patients

Trial24 months172 peopleBothmean 62 ± 10 yearsPatient cohortsESC Congress 2026 abstract, Oct 26, 2026

up: Increases achievement of LDL-C <55 mg/dL91.7% versus 65.0%; RR 1.41, 95% CI 1.12–1.78; p=0.02

down: Decreases treatment-emergent adverse events18.3% versus 28.0%; p=0.04

Randomized trial5 months112 peopleBothmean 68 yearsOlder adults; Ischemic HFrEF on atorvastatin 80 mg and ezetimibe 10 mgESC Congress 2026 abstract, Oct 26, 2026

up: Increases LDL-C goal attainmentD90: 85.1% vs 31.0%; D360: 89.5% vs 62.2%

down: Decreases need for LLT escalation12.5% vs 52.8% requiring >20 mg rosuvastatin

down: Decreases muscle-related adverse events33.3% vs 60.5%; OR 0.34

Randomized trial360 days1,770 peopleInclisiran-based therapy compared with individually optimized lipid-lowering therapyESC Congress 2026 abstract, Oct 26, 2026

down: Decreases low-density lipoprotein cholesterol−40.95% (95% CI: −45.67 to −36.24)

up: Improves LDL-C goal attainment78.2% vs 20.3%, aOR 16.36 (95% CI 9.72 to 27.54)

Randomized trial150 days402 people64.2% menmean ± standard deviation age, 63.1 ± 10.7 yearsASCVD patients with LDL-C ≥70 mg/dl on statins (± ezetimibe)European heart journal, Aug 31, 2026

What did studies of inclisiran find?

36

Studies of inclisiran measured 36 outcomes; the most studied are LDL-C (20 studies), LDL cholesterol (14) and low-density lipoprotein cholesterol (6).

LDL-C

downin humans18downin reviews2no changein humans1−56% to −48%

20 studies
  1. Inclisiran decreases LDL-C in humans (added to statin therapy) (51% reduction (4.8 to 2.3 mmol/L)).

    “Inclisiran plus statin therapy resulted in a mean LDL-C reduction of 51% (baseline 4.8 ± 0.5 → 2.3 ± 0.4 mmol/L, p<0.001)”

    Human trialadded to statin therapy300 mg subcutaneously at baseline, 3 months, then every 6 months24 monthsn = 172

    Inclisiran in combination with statin therapy achieves profound LDL-C and lipoprotein(a) reduction without acute cardiovascular events in high-risk patients with familial hypercholesterolemia

    ESC Congress 2026 abstract

  2. Inclisiran decreases LDL-C in humans (versus bempedoic acid at Day 150) (least squares mean -56.3% vs -15.4%; between-group difference -41.0%).

    “LDL-C reduction at Day 150 was superior with inclisiran vs BPA”

    Human trialversus bempedoic acid at Day 150Day 150

    Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial

    European heart journal

  3. Inclisiran decreases LDL-C in humans (elevated LDL-C, low/moderate ASCVD risk, monotherapy) (-47.50%).

    “inclisiran significantly reduced LDL-C vs placebo on Day 150 (least squares mean [LSM] difference: -47.50%; P < 0.0001)”

    Human trialelevated LDL-C, low/moderate ASCVD risk, monotherapy150 daysn = 207

    Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial

    Journal of clinical lipidology

  4. Inclisiran decreases LDL-C in humans (chronic kidney disease stage V) (< 55 mg/dL).

    “After 3 and 12 months, he attained the LDL–C target of ‹ 55 mg/dL.”

    Human trialchronic kidney disease stage V284 mg s.c.12 monthsn = 1

    INCLISIRAN IN TWO VERY–HIGH CV RISK PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE

    European Heart Journal Supplements

  5. Inclisiran decreases LDL-C in humans (dyslipidemia and atherosclerotic plaques in peripheral arteries) (-65% (to 1.3 [1.2; 2.9] mmol/L, p<0.01)).

    “Ninety days post-initiation of inclisiran, LDL-C was reduced by 65% (to 1.3 [1.2; 2.9] mmol/L, p<0.01)”

    Human trialdyslipidemia and atherosclerotic plaques in peripheral arteries90 daysn = 22

    Inclisiran Therapy and Lipid Profile Dynamics in Real-World Clinical Practice in Russia: Interim Results of an Observational Study

    Kardiologiia

  6. Inclisiran decreases LDL-C in humans (WMD –48.99%, 95% CI –54.29 to –43.69).

    “Inclisiran significantly reduced: LDL-C (WMD –48.99%, 95% CI: –54.29 to –43.69)”

    Human trial

    Updated Meta-Analysis of Randomized Controlled Trials Evaluating the Safety and Efficacy of Inclisiran in Hyperlipidemia

    AHA Scientific Sessions 2025 abstract

  7. Inclisiran decreases LDL-C in humans (−50.4% vs 0.2%, P<0.001).

    “LDLleast C least squares mean percentage change from baseline at Day 90 was significantly greater with inclisiran + usual care vs usual care (LLT: −50.4% vs 0.2%; no LLT: −46.2% vs 5.5%; both P<0.001)”

    Human trialwith usual care in participants with recent acute coronary syndrome receiving index lipid-lowering therapy300 mg (284 mg inclisiran equivalent) on Days 0, 90, and 270Day 90

    VICTORION-INCEPTION: Consistent Low-density Lipoprotein Cholesterol Lowering With Inclisiran Following Acute Coronary Syndrome Independent of Index Lipid-lowering Therapy

    AHA Scientific Sessions 2025 abstract

  8. Inclisiran is linked with lower LDL-C in humans (-46% (95% CI -60.8 to -33.8%)).

    “Median (95% CI) LDL-C reduction from baseline to nadir was - 46% (- 60.8 to - 33.8%).”

    Humansup to 3 yearsn = 109

    Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network

    Clinical research in cardiology : official journal of the German Cardiac Society

  9. Inclisiran is linked with lower LDL-C in humans after six administrations over two years (72.5% reduction from baseline (3.02 to 0.83 mmol/L)).

    “After two years (six drug administrations), LDL-C was reduced to 0,83 mmol/L, corresponding to a 72,5% reduction from baseline”

    Humansafter six administrations over two yearssix administrationstwo yearsn = 1

    An integrated approach to a multimorbid patient with extreme risk of cardiovascular events. A case report

    Russian Journal of Cardiology

  10. Inclisiran is linked with lower LDL-C in humans (real-world cohort at a tertiary lipid service) (mean reduction 48.4% after first dose).

    “Inclisiran therapy resulted in a mean LDL-C reduction of 48.4% following the first dose, sustained over 27 months.”

    Humansreal-world cohort at a tertiary lipid servicefirst dose27 monthsn = 238

    Real-world efficacy of inclisiran: data from a tertiary lipid clinic

    The British journal of cardiology

All 21

More on LDL-C

LDL cholesterol

downin humans13downin reviews1−50% sustained ldl-c reduction

14 studies
  1. Inclisiran decreases LDL cholesterol in humans (-49.9% to -54.7% (P < 0.001)).

    “The mean (95% confidence interval) placebo-corrected percentage changes in LDL cholesterol from baseline at day 510 in patients with eGFR ≥90, 60 to <90, 45 to <60, and 15 to <45 ml/min per 1.73 m 2 were -49.9% (-53.2 to -46.6), -51.2% (-54.4 to -48.0), -54.7% (-62.5 to -47.0), and -44.7% (-57.6 to -31.8), respectively ( P < 0.001)”

    Human trialsubcutaneous510 days

    Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials

    Journal of the American Society of Nephrology : JASN

  2. Inclisiran decreases LDL cholesterol in humans (heterozygous familial hypercholesterolaemia on maximally tolerated statin treatment) (-28·5% (95% CI -35·8 to -21·3; p<0·0001)).

    “with a between-group difference of -28·5% (95% CI -35·8 to -21·3; p<0·0001)”

    Human trialheterozygous familial hypercholesterolaemia on maximally tolerated statin treatmentinclisiran sodium300 mgday 330n = 141

    Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial

    The lancet. Diabetes & endocrinology

  3. Inclisiran is linked with lower LDL cholesterol in humans (hypercholesterolemia) (50% reduction).

    “inclisiran reduced LDL-C by 50% and plasma PCSK9 by 56% at month 3.”

    Humanshypercholesterolemiaplasma3 monthsn = 19

    Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Associates with a LDL Subfraction: Ex vivo and in vitro Studies

    AHA Scientific Sessions 2026 abstract

  4. Inclisiran is linked with lower LDL cholesterol in humans (high, very high or extremely high cardiovascular risk) (−47.5 ± 26.0%; 118.2 ± 48.9 to 60.3 ± 36.3 mg/dL).

    “Mean LDL-C decreased from 118.2 ± 48.9 to 60.3 ± 36.3 mg/dL (−47.5 ± 26.0%; p < 0.001)”

    Humanshigh, very high or extremely high cardiovascular risk15 months

    Long-term real-world efficacy of inclisiran at 15 months: new results from the INCLIVEN multicenter registry

    Atherosclerosis plus

  5. Inclisiran is linked with lower LDL cholesterol in humans (Routine clinical practice) (Median reductions: 48.9% at 3 months, 51.8% at 9 months, 51.2% at 15 months, and 48.0% at 21 months).

    “In real-world practice, inclisiran shows sustained LDL-C reduction up to 21 months, with approximately 50% target attainment and low discontinuation rates.”

    HumansRoutine clinical practiceUp to 21 months67.2% malesn = 1,428

    Long term efficacy and adherence of inclisiran in real-world clinical practice: insights from the CHOLINET Registry

    ESC Congress 2026 abstract

  6. Inclisiran is linked with lower LDL cholesterol in two people with HIV on stable ART, after subcutaneous dosing at Day 1 and Day 90 (80.2% and 54.6% LDL-C reduction at Month 6).

    “Case 1 achieved an 80.2% LDL-C reduction to 28 mg/dL at Month 6, and Case 2 achieved a 54.6% reduction to 88 mg/dL at Month 6 as monotherapy.”

    Humansin two people with HIV on stable ART, after subcutaneous dosing at Day 1 and Day 906 monthsmalesn = 2

    The Utilization of Inclisiran for the Optimization of Lipid Management in People Living with HIV: A Clinical Case Series and Comprehensive Review

    Reports (MDPI)

  7. Inclisiran is linked with lower LDL cholesterol in routine clinical practice (median approximately -25% to -40% across follow-up visits).

    “Median LDL-C reduction ranged from approximately - 25% to - 40% across follow-up visits.”

    Humansin routine clinical practicemedian follow-up 18 monthsn = 67

    Inclisiran-induced LDL-cholesterol reduction with and without concomitant statin therapy: a real-world analysis

    BMC cardiovascular disorders

  8. Inclisiran is linked with lower LDL cholesterol in humans (−33.2% (−1.17 mmol/L), unadjusted).

    “mean unadjusted LDL-C reductions were − 58.2% (–1.98 mmol/L), − 58.9% (–2.09 mmol/L), and − 33.2% (–1.17 mmol/L), respectively (p < 0.001).”

    Humansn = 94

    Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study

    Lipids in health and disease

  9. Inclisiran is linked with lower LDL cholesterol in humans (chronic kidney disease and chronic ischemic heart disease) (almost 50% reduction).

    “After 12 months of treatment, there was almost 50% reduction in both total and LDL cholesterol values”

    Humanschronic kidney disease and chronic ischemic heart disease284 mg12 monthsn = 32

    Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience

    Cardiorenal medicine

  10. Inclisiran decreases LDL cholesterol in humans (chronic kidney disease).

    “Evolocumab, alirocumab, and inclisiran consistently lowered low-density lipoprotein cholesterol”

    Reviewchronic kidney disease

    PCSK9-Targeted Therapy and Kidney Function in Chronic Kidney Disease: A Systematic Review and Narrative Synthesis

    Clinical therapeutics

All 14

More on LDL cholesterol

Low-density lipoprotein cholesterol

downin humans6−60% to −50% reduction

6 studies
  1. Inclisiran decreases low-density lipoprotein cholesterol in humans (−40.95% (95% CI: −45.67 to −36.24)).

    “Inclisiran demonstrated superior efficacy vs BPA in lowering LDL-C, meeting the primary efficacy objective of the study.”

    Human trial150 daysn = 402

    Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial

    European heart journal

  2. Inclisiran is linked with lower low-density lipoprotein cholesterol in humans (117.4 to 45.9 mg/dL).

    “The LDL-C levels decreased from 117.4 mg/dL (95% confidence interval [CI], 113.3-121.6) to 45.9 mg/dL (39.5-52.3) at 15 months.”

    Humans15 months

    Serial Coronary Plaque Composition After Inclisiran Initiation Assessed by Automated CCTA: A Retrospective Pilot Study

    Diagnostics (Basel, Switzerland)

  3. Inclisiran is linked with lower low-density lipoprotein cholesterol in humans (real-world clinical practice) (-44.7% after 1st dose, -40.8% after 2nd dose).

    “Median LDL-C reduction after the 1st and 2nd doses was 44.7% and 40.8%, respectively.”

    Humansreal-world clinical practicen = 95

    Real-world assessment of adherence to inclisiran dosing schedule and LDL-C reduction in patients with hypercholesterolemia in Austria

    Journal of clinical lipidology

  4. Inclisiran is linked with lower low-density lipoprotein cholesterol in humans with statin ± ezetimibe (59.5% reduction).

    “At 15 months, the mean low-density lipoprotein cholesterol (LDL-C) levels decreased by 59.5% in patients receiving statin ± ezetimibe”

    Humanswith statin ± ezetimibe15 months

    Inclisiran safety and efficacy in real-world clinical practice: results of a retrospective observational investigation

    Journal of cardiovascular medicine (Hagerstown, Md.)

  5. Inclisiran is linked with lower low-density lipoprotein cholesterol in humans (-46.8% (95% CI 42.7-51.0)).

    “Mean absolute LDL-C reduction was 66.1 (standard deviation: 45.6) mg/dl, corresponding to a 46.8% (95% confidence interval: 42.7-51.0) relative reduction”

    Humans12 monthsn = 202

    Real-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up

    Cardiology and therapy

  6. Inclisiran decreases low-density lipoprotein cholesterol in humans (approximately 50% reduction).

    “Inclisiran reduced low-density lipoprotein cholesterol by approximately 50% with twice-yearly dosing”

    Reviewtwice-yearly dosing

    RNA-Targeted Therapeutics in Cardiovascular Risk Reduction: From Gene Silencing to Precision Cardiology

    Cardiology in review

More on Low-density lipoprotein cholesterol

Lipoprotein

downin humans5−33% to −18%

5 studies
  1. Inclisiran decreases lipoprotein in humans (added to statin therapy) (27% reduction (70 to 51 mg/dL)).

    “and Lp(a) reduction of 27% (baseline 70 ± 15 → 51 ± 12 mg/dL, p<0.001)”

    Human trialadded to statin therapy300 mg subcutaneously at baseline, 3 months, then every 6 months24 monthsn = 172

    Inclisiran in combination with statin therapy achieves profound LDL-C and lipoprotein(a) reduction without acute cardiovascular events in high-risk patients with familial hypercholesterolemia

    ESC Congress 2026 abstract

  2. Inclisiran decreases lipoprotein in humans (elevated LDL-C, low/moderate ASCVD risk, monotherapy) (-30.27%).

    “inclisiran induced a significant (P < 0.0001) reduction in other atherogenic lipoproteins and lipid biomarkers (placebo-adjusted LSM difference: lipoprotein(a), -30.27%”

    Human trialelevated LDL-C, low/moderate ASCVD risk, monotherapy150 daysn = 207

    Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial

    Journal of clinical lipidology

  3. Inclisiran decreases lipoprotein in humans (dyslipidemia and atherosclerotic plaques in peripheral arteries) (-33%).

    “and Lp(a) by 33%”

    Human trialdyslipidemia and atherosclerotic plaques in peripheral arteries90 daysn = 22

    Inclisiran Therapy and Lipid Profile Dynamics in Real-World Clinical Practice in Russia: Interim Results of an Observational Study

    Kardiologiia

  4. Inclisiran is linked with lower lipoprotein in humans (unadjusted analyses) (-8% to -17%).

    “and from -8% to -17% with inclisiran”

    Humansunadjusted analyses

    Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study

    Atherosclerosis

  5. Inclisiran decreases lipoprotein in humans (meta-analyses of RCTs) (18.00%).

    “and inclisiran (18.00%; high certainty).”

    Reviewmeta-analyses of RCTs

    Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials

    Drugs

More on Lipoprotein

Muscle-related adverse events

downin humans2OR 0.34–0.57

2 studies
  1. Inclisiran decreases muscle-related adverse events in humans among participants on no rosuvastatin (33.3% vs 60.5%; OR 0.34).

    “Significantly fewer muscle-related AEs occurred with inclisiran-based therapy vs ioLLT among those on no rosuvastatin (33.3% vs 60.5%; odds ratio [OR], 0.34; 95% confidence interval [CI], 0.13–0.85)”

    Human trialamong participants on no rosuvastatin360 days

    Inclisiran helped more high-risk people reach cholesterol goals

    ESC Congress 2026 abstract

  2. Inclisiran decreases muscle-related adverse events in humans (hypercholesterolemia at high or very high CV risk on maximally tolerated dose of statins) (11.9% vs. 19.2%, OR 0.57 (95% CI: 0.43, 0.74)).

    “Fewer participants in the inclisiran vs. SOC arm experienced a MRAE (11.9% vs. 19.2%; odds ratio=0.57; 95% CI: 0.43, 0.74).”

    Human trialhypercholesterolemia at high or very high CV risk on maximally tolerated dose of statins300 mg subcutaneous360 daysn = 1,770

    Effect Of Inclisiran-based Treatment Strategy, In Combination With Individually Optimized Statin Therapy, On Quality Of Life And Muscle-related Pain vs. Standard of Care: Exploratory Outcomes From The VICTORION-Difference Study

    AHA Scientific Sessions 2025 abstract

LDL-C goal attainment

upin humans2

2 studies
  1. Inclisiran increases LDL-C goal attainment in humans (inclisiran-based therapy compared with individually optimized lipid-lowering therapy) (D90: 85.1% vs 31.0%; D360: 89.5% vs 62.2%).

    “More participants achieved LDL-C goals with inclisiran-based therapy vs ioLLT (D90: 85.1% vs 31.0%; D360: 89.5% vs 62.2%).”

    Human trialinclisiran-based therapy compared with individually optimized lipid-lowering therapy360 days

    Inclisiran helped more high-risk people reach cholesterol goals

    ESC Congress 2026 abstract

  2. Inclisiran increases LDL-C goal attainment in humans (versus bempedoic acid) (78.2% vs 20.3%; adjusted odds ratio 16.36, 95% CI 9.72 to 27.54).

    “with higher LDL-C goal attainment (78.2% vs 20.3%; adjusted odds ratio 16.36, 95% CI 9.72 to 27.54; descriptive p<0.0001)”

    Human trialversus bempedoic acid

    Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial

    European heart journal

More on LDL-C goal attainment

Treatment-emergent adverse events

downin humans1no changein humans1

2 studies
  1. Inclisiran decreases treatment-emergent adverse events in humans (Ischemic HFrEF on atorvastatin 80 mg and ezetimibe 10 mg; compared with evolocumab) (18.3% versus 28.0%; p=0.04).

    “The incidence of TEAEs was lower with Inclisiran (18.3% vs. 28.0%; p=0.04), driven mainly by fewer injection-site reactions (10.5% vs. 17.0%).”

    Human trialIschemic HFrEF on atorvastatin 80 mg and ezetimibe 10 mg; compared with evolocumabsiRNA284 mg5 months75% malesn = 112

    The LUNAR-HF Trial: a randomised comparison of inclisiran versus evolocumab in ischaemic heart failure with reduced ejection fraction

    ESC Congress 2026 abstract

  2. Inclisiran showed no clear effect on treatment-emergent adverse events in humans (versus bempedoic acid) (63.1% vs 59.8%).

    “comparable rates of TEAEs (63.1% vs 59.8%) and serious TEAEs (5.9% vs 7.5%)”

    Human trialversus bempedoic acid

    Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial

    European heart journal

Adverse events

upin humans2RR 1.06

2 studies
  1. Inclisiran increases adverse events in humans (RR 1.06; p=0.02).

    “Total adverse events were slightly higher with inclisiran (RR 1.06; p=0.02)”

    Human trial

    Updated Meta-Analysis of Randomized Controlled Trials Evaluating the Safety and Efficacy of Inclisiran in Hyperlipidemia

    AHA Scientific Sessions 2025 abstract

  2. Inclisiran is linked with adverse events in humans (atherosclerotic cardiovascular disease or HeFH) (4% (24 patients)).

    “AEs were reported by 24 patients (4%), of whom 12 (50%) discontinued treatment.”

    Humansatherosclerotic cardiovascular disease or HeFHn = 562

    Low-density lipoprotein cholesterol lowering and out-of-pocket cost of inclisiran therapy in the United States

    Journal of clinical lipidology

Total cholesterol

downin humans2

2 studies
  1. Inclisiran decreases total cholesterol in humans (dyslipidemia and atherosclerotic plaques in peripheral arteries) (-30% (p<0.01)).

    “TC by 30% (p<0.01)”

    Human trialdyslipidemia and atherosclerotic plaques in peripheral arteries90 daysn = 22

    Inclisiran Therapy and Lipid Profile Dynamics in Real-World Clinical Practice in Russia: Interim Results of an Observational Study

    Kardiologiia

  2. Inclisiran is linked with lower total cholesterol in humans (chronic kidney disease and chronic ischemic heart disease) (almost 50% reduction).

    “After 12 months of treatment, there was almost 50% reduction in both total and LDL cholesterol values”

    Humanschronic kidney disease and chronic ischemic heart disease284 mg12 monthsn = 32

    Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience

    Cardiorenal medicine

More on Total cholesterol

Hepatic PCSK9 synthesis

downin humans1

1 study
  1. Inclisiran inhibits hepatic PCSK9 synthesis in humans.

    “inclisiran, a small interfering RNA (siRNA), achieves sustained suppression of hepatic PCSK9 synthesis with infrequent dosing.”

    Reviewsmall interfering RNA (siRNA)liver

    PCSK9 Inhibition in Transition: From Established Treatments to Emerging Therapeutic Approaches

    International journal of molecular sciences

Liver enzyme elevation

upin humans1+6% patients

1 study
  1. Inclisiran increases liver enzyme elevation in humans (added to statin therapy) (6% of patients).

    “mild transient liver enzyme elevations occurred in 6% of patients”

    Human trialadded to statin therapy24 monthsn = 172

    Inclisiran in combination with statin therapy achieves profound LDL-C and lipoprotein(a) reduction without acute cardiovascular events in high-risk patients with familial hypercholesterolemia

    ESC Congress 2026 abstract

More on Liver enzyme elevation

Need for LLT escalation

downin humans1

1 study
  1. Inclisiran decreases need for LLT escalation in humans (inclisiran-based therapy compared with individually optimized lipid-lowering therapy) (12.5% vs 52.8% requiring >20 mg rosuvastatin).

    “By D360, 64.8% of those on inclisiran-based therapy vs 12.5% on ioLLT had ≤10 mg rosuvastatin; fewer required >20 mg (12.5% vs 52.8%; Table).”

    Human trialinclisiran-based therapy compared with individually optimized lipid-lowering therapy>20 mg rosuvastatin360 days

    Inclisiran helped more high-risk people reach cholesterol goals

    ESC Congress 2026 abstract

Achievement of LDL-C <55 mg/dL

upin humans1RR 1.41

1 study
  1. Inclisiran increases achievement of LDL-C <55 mg/dL in humans (Ischemic HFrEF on atorvastatin 80 mg and ezetimibe 10 mg; compared with evolocumab) (91.7% versus 65.0%; RR 1.41, 95% CI 1.12–1.78; p=0.02).

    “the primary endpoint was achieved by 91.7% (11/12) of patients in the Inclisiran group versus 65.0% (65/100) in the Evolocumab group”

    Human trialIschemic HFrEF on atorvastatin 80 mg and ezetimibe 10 mg; compared with evolocumabsiRNA284 mg5 months75% malesn = 112

    The LUNAR-HF Trial: a randomised comparison of inclisiran versus evolocumab in ischaemic heart failure with reduced ejection fraction

    ESC Congress 2026 abstract

More on Achievement of LDL-C <55 mg/dL

LDL-C goal attainment

upin humans1

1 study
  1. Inclisiran improves LDL-C goal attainment in humans (78.2% vs 20.3%, aOR 16.36 (95% CI 9.72 to 27.54)).

    “At Day 150, a higher proportion of patients treated with inclisiran achieved their individual guideline-recommended LDL-C targets compared with BPA (78.2% vs 20.3%; adjusted odds ratio (aOR) 16.36 [95% CI 9.72 to 27.54]; P <.0001) (Figure 4A).”

    Human trial150 daysn = 402

    Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial

    European heart journal

ApoB

downin humans1−37%

1 study
  1. Inclisiran decreases ApoB in humans (elevated LDL-C, low/moderate ASCVD risk, monotherapy) (-36.84%).

    “nonhigh-density lipoprotein cholesterol, -40.57%; apolipoprotein B, -36.84%”

    Human trialelevated LDL-C, low/moderate ASCVD risk, monotherapy150 daysn = 207

    Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial

    Journal of clinical lipidology

More on ApoB

All 36

What is inclisiran linked with?

15

Studies link inclisiran with 15 measures, among them LDL-C, acute kidney injury and all-cause hospitalization.

LDL-C

downin humans1

1 study
  1. Inclisiran is associated with LDL-C in humans (Median LDL-C reduction of 77% at day 14; baseline 138 mg/dL and day 14 31 mg/dL).

    “Baseline LDL-C was 138 mg/dL and fell to 75 and 31 mg/dL at days 3 and 14 after the dose (median reductions 45% and 77%).”

    HumansIschemic stroke; combined with intensified oral therapy, whose contribution cannot be isolated284 mg14 daysn = 15

    In-hospital inclisiran for early LDL-C lowering after atherosclerotic ischemic stroke: an observational pilot study

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

More on LDL-C

Acute kidney injury

downin humans1HR 0.62

1 study
  1. Inclisiran is associated with acute kidney injury in humans (10.4% vs 19.2%; HR 0.62, 95% CI 0.41–0.95).

    “and acute kidney injury (10.4% vs 19.2%; HR, 0.62; 95% CI, 0.41 - 0.95; p=0.03).”

    HumansMASLD and elevated cardiovascular risk; receiving statin and ezetimibe therapy; compared with no inclisiran3 yearsn = 317

    Cardiovascular Outcomes of Inclisiran in Patients with Elevated Cardiovascular Risk and Metabolic Dysfunction Associated Steatotic Liver Disease

    AHA Scientific Sessions 2026 abstract

More on Acute kidney injury

All-cause hospitalization

downin humans1HR 0.58

1 study
  1. Inclisiran is associated with all-cause hospitalization in humans (25.6% vs 44.8%; HR 0.58, 95% CI 0.44–0.76).

    “Inclisiran use was associated with lower three-year hazards of all-cause hospitalization compared with no inclisiran”

    HumansMASLD and elevated cardiovascular risk; receiving statin and ezetimibe therapy; compared with no inclisiran3 yearsn = 317

    Cardiovascular Outcomes of Inclisiran in Patients with Elevated Cardiovascular Risk and Metabolic Dysfunction Associated Steatotic Liver Disease

    AHA Scientific Sessions 2026 abstract

Mortality

downin humans1HR 0.639

1 study
  1. Inclisiran is associated with mortality in humans (Compared with evolocumab in patients with atherosclerotic heart disease and dyslipidemia) (HRs 0.639, 0.670, and 0.695 at 1, 3, and 5 years; not significant).

    “Inclisiran showed lower mortality than evolocumab (HRs 0.639, 0.670, 0.695)”

    HumansCompared with evolocumab in patients with atherosclerotic heart disease and dyslipidemia1, 3, and 5 years

    Comparative Cardiovascular Outcomes Across PCSK9-Targeted Therapies: A Real-World Matched Cohort Analysis of Inclisiran, Alirocumab, and Evolocumab

    AHA Scientific Sessions 2026 abstract

Major adverse cardiovascular events

downin humans1RR 0.74

1 study
  1. Inclisiran lowers the risk of major adverse cardiovascular events in humans (Symptomatic peripheral artery disease; versus control) (RR 0.74, 95% CI 0.63-0.87; NNT=24).

    “MACE was significantly lower (RR 0.74, 95% CI 0.63-0.87; p=0.0002; NNT=24).”

    ReviewSymptomatic peripheral artery disease; versus controlMedian follow-up 24 monthsn = 6,741

    RNA Interference Therapy with Inclisiran versus Statin Intensification in Peripheral Artery Disease: Limb Salvage and Major Adverse Cardiovascular and Limb Events: A Systematic Review and Meta-Analysis

    AHA Scientific Sessions 2026 abstract

Major adverse limb events

downin humans1RR 0.69

1 study
  1. Inclisiran lowers the risk of major adverse limb events in humans (Symptomatic peripheral artery disease; versus control) (RR 0.69, 95% CI 0.58-0.82; NNT=18).

    “MALE was significantly reduced (RR 0.69, 95% CI 0.58-0.82; p<0.0001; NNT=18).”

    ReviewSymptomatic peripheral artery disease; versus controlMedian follow-up 24 monthsn = 6,741

    RNA Interference Therapy with Inclisiran versus Statin Intensification in Peripheral Artery Disease: Limb Salvage and Major Adverse Cardiovascular and Limb Events: A Systematic Review and Meta-Analysis

    AHA Scientific Sessions 2026 abstract

Achievement of any LDL-C reduction

upin humans1RR 1.27

1 study
  1. Inclisiran is associated with achievement of any LDL-C reduction in humans (Hypercholesterolemia; compared with PCSK9 monoclonal antibodies) (45.9% vs 36.0%; RR 1.27, 95% CI 1.13-1.43).

    “inclisiran was associated with a higher proportion of patients achieving any LDL-C reduction (45.9% vs 36.0%; RR 1.27, 95% CI 1.13-1.43; P<0.001)”

    HumansHypercholesterolemia; compared with PCSK9 monoclonal antibodies90- to 365-day window after initiationn = 844

    Comparative Lipid Outcomes with Inclisiran versus PCSK9 Monoclonal Antibodies in Hypercholesterolemia: A Propensity Score Matches Observational Study

    AHA Scientific Sessions 2026 abstract

LDL cholesterol

downin humans1

1 study
  1. Inclisiran is associated with LDL cholesterol in humans (LDL-C −29.5%; total cholesterol −22.6%; triglycerides −29.0%).

    “LDL-C was reduced by 29.5%, total cholesterol by 22.6%, and triglycerides by 29.0% (all P < 0.01).”

    Humansn = 45

    Impact of inclisiran on the cardiometabolic–inflammatory index: a real-world observational study

    ESC Congress 2026 abstract

More on LDL cholesterol

Cardiometabolic inflammation index

downin humans1

1 study
  1. Inclisiran is associated with cardiometabolic inflammation index in humans (Absolute change −0.44; 95% CI −0.63 to −0.24; −8.24%).

    “Mean CTI decreased from 5.32 ± 0.70 at baseline to 4.88 ± 0.53 at follow-up”

    Humansn = 45

    Impact of inclisiran on the cardiometabolic–inflammatory index: a real-world observational study

    ESC Congress 2026 abstract

More on Cardiometabolic inflammation index

Rehospitalization for ischemic events

downin humans1

1 study
  1. Inclisiran is associated with rehospitalization for ischemic events in humans after two years of treatment (none reported).

    “with no rehospitalizations for ischemic events”

    Humansafter two years of treatmenttwo yearsn = 1

    An integrated approach to a multimorbid patient with extreme risk of cardiovascular events. A case report

    Russian Journal of Cardiology

All 15

Has inclisiran been tested in people?

7 of 51 about aging

Yes: 14 trials and 34 observational studies in people have been published, and 44 trials are registered.

Approved

  • FDA Leqvio

    Dec 22, 2021Homozygous Familial Hypercholesterolemia, Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia

Repurposing

All 22

Every condition in trials

  • Hyperlipidemias

    Phase 4Active, not recruiting9 trials

  • Hyperlipoproteinemia type II

    Phase 3Recruiting4 trials

  • Familial hypercholesterolemia heterozygous

    Phase 3Results posted1 trial

Who is developing inclisiran?

2 companies: Novartis Pharmaceuticals and Shanghai Minwei Biotechnology.

Companies
  • Novartis PharmaceuticalsPhase 4acute coronary syndrome, hypercholesterolemia
  • Shanghai Minwei BiotechnologyPhase 2mixed dyslipidemia

Trial sponsors

Latest

Dec 2025: 4Jan 2026: 9Feb 2026: 12Mar 2026: 6Apr 2026: 1May 2026: 1Jun 2026: 1Jul 2026: 2Aug 2026: 10Sep 2026: 5Oct 2026: 20Nov 2026: 2394 papers in 12 months

See all 109 papers on inclisiran